BioRestorative Therapies Inc BRTX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if BRTX is a good fit for your portfolio.
News
-
BioRestorative Therapies’ Chief Scientist Named New Section Editor of the Prestigious Journal of Translational Medicine
-
BioRestorative Therapies Announces Notice of Allowance for Patent Covering Fundamental Aspect of ThermoStem® Metabolic Disease Program
-
BioRestorative Therapies Regains Compliance with Nasdaq Listing Rule 5250(c)(1); Reports First Quarter 2024 Financial Results
-
BioRestorative Therapies in Substantive Discussions for Potential License Agreement for ThermoStem® Metabolic Disease Program
-
BioRestorative Therapies, Inc. to attend the Jefferies 2024 Healthcare Conference
-
BioRestorative Therapies Announces Receipt of Nasdaq Non-Compliance Notice
-
BioRestorative Therapies (NASDAQ:BRTX) Announces Commercial Agreement With Cartessa, Further Expanding Into $75.46 Billion Aesthetics Market
-
BioRestorative Therapies Provides First Quarter 2024 Business Update
Trading Information
- Previous Close Price
- $1.67
- Day Range
- $1.53–1.69
- 52-Week Range
- $1.03–3.67
- Bid/Ask
- $1.54 / $1.79
- Market Cap
- $10.97 Mil
- Volume/Avg
- 46,349 / 2.0 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 53.71
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, primarily involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 11
- Website
- https://www.biorestorative.com
Valuation
|
Metric
|
BRTX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.76 |
Price/Sales | 53.71 |
Price/Cash Flow | — |
Price/Earnings
BRTX
Financial Strength
|
Metric
|
BRTX
|
|---|---|
Quick Ratio | 4.77 |
Current Ratio | 4.86 |
Interest Coverage | — |
Quick Ratio
BRTX
Profitability
|
Metric
|
BRTX
|
|---|---|
Return on Assets (Normalized) | −3.65% |
Return on Equity (Normalized) | −4.15% |
Return on Invested Capital (Normalized) | −9.50% |
Return on Assets
BRTX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk A/S ADR
NVO
| Qnqbbwty | Hjmc | $565.6 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Nmwthrjfx | Tnrzd | $127.8 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Ntzzbwrc | Xdncbpm | $118.7 Bil | |||
| Moderna Inc
MRNA
| Bpkfstd | Pbg | $46.8 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Jqvmnvmsz | Rwvltp | $29.7 Bil | |||
| argenx SE ADR
ARGX
| Qvkmkfnqr | Gwll | $29.3 Bil | |||
| BioNTech SE ADR
BNTX
| Ymyzjjl | Wcxhx | $20.7 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Kjkwgyfyc | Czpsgf | $16.1 Bil | |||
| United Therapeutics Corp
UTHR
| Rzgvpyd | Ttl | $15.0 Bil | |||
| Incyte Corp
INCY
| Pvwjnrsh | Wlmrwpp | $13.5 Bil |